Licensing status

Publication and contact information


Plasma levels of the CDKN1A interacting zinc finger protein 1 (CIZ1) truncated variant to diagnose early stage lung cancer

Patient sample and mouse studies suggest plasma levels of truncated CIZ1 could help diagnose early stage lung cancer. In plasma samples from 40 patients with stage 1 lung cancer and 120 controls, an antibody targeting truncated CIZ1 identified the cancers with 95% accuracy and up to 74% specificity. In mouse xenograft models of human lung cancer, small hairpin RNA targeting the truncated CIZ1 decreased tumor cell proliferation compared with control shRNA. Next steps include developing a high throughput quantitative immunoassay.

SciBX 5(43); doi:10.1038/scibx.2012.1150
Published online Nov. 1, 2012

Findings patented by Cizzle Biotechnology Ltd.; available for licensing

Higgins, G. et al. Proc. Natl. Acad. Sci. USA; published online Oct. 16, 2012;
Contact: Dawn Coverley, The University of York, Yorkshire, U.K.